Welcome to our dedicated page for Rapid Dose Thera news (Ticker: RDTCF), a resource for investors and traders seeking the latest updates and insights on Rapid Dose Thera stock.
Rapid Dose Therapeutics Corp. (RDTCF / CSE: DOSE) is a Canadian biotechnology and life sciences company centered on its QuickStrip™ oral thin-film drug delivery platform. The news flow around the company frequently combines product development updates with financing and corporate actions, giving investors insight into both its technology progress and its capital structure.
Readers of this news page can follow announcements on QuickStrip™-based initiatives, including nicotine-focused products such as QuickStrip™ Nicotine and NicStrip™, as well as harm reduction applications like the Replace+ sublingual cannabis strip developed with Eco Canadian Organic Inc. News releases have covered regulatory milestones such as a Health Canada submission for QuickStrip™ Nicotine in multiple dose strengths and details of a pharmacokinetic clinical study comparing nicotine absorption to combustible cigarettes.
In addition to product and partnership updates, Rapid Dose Therapeutics regularly reports on financing-related developments. These include private placement financings involving secured convertible notes and warrants, extensions of note maturities and warrant expiries, and the issuance of common shares to pay accrued interest on secured debt. The company has also disclosed shares-for-debt transactions with creditors and directors aimed at reducing outstanding liabilities.
By reviewing the news items linked on this page, investors and observers can track how Rapid Dose Therapeutics advances its QuickStrip™ technology across nicotine, cannabis, nutraceutical and pharmaceutical applications, while also monitoring share issuances, note terms and other corporate actions that affect its capital structure. This page is a central source for the company’s publicly released updates and disclosures.
Rapid Dose Therapeutics (OTCQB: RDTCF) provided a strategic update on March 26, 2026, highlighting IP expansion, clinical progress, and international launches. Key items include an India patent grant (IN 582202), an ANVISA-backed QuickStrip launch in Brazil, ongoing PK trials with a tobacco partner, and an OTCQB U.S. listing.
The company reports CBD bioavailability study enrollment >60% and emphasizes priorities: global market expansion, distribution strengthening, clinical validation, and securing Canadian pharmaceutical manufacturing approval.
Rapid Dose Therapeutics (OTCQB: RDTCF) announced that the Indian Patent Office granted Patent No. IN 582202 for its QuickStrip™ Nicotine Bilayer Oral Film on March 5, 2026. The patent covers bilayer oral thin film formulation and manufacturing for controlled, rapid nicotine delivery.
The company filed the underlying PCT application July 22, 2024 and filed a WIPO PCT in May 2025 that extends potential protection to 158 jurisdictions. Market data cites a projected $38.89B modern oral nicotine market by 2033 (19% CAGR).
Rapid Dose Therapeutics (OTCQB: RDTCF) updated progress on cannabinoid research and clinical evaluation of its QuickStrip oral thin film delivery platform.
Independent academic studies supported by grant funding from the NFL are examining cannabinoids for concussion-related pain and neuroprotection. A separate clinical arm, started Q2 2024, is comparing CBD bioavailability from QuickStrip versus traditional oral formats; raw data have been extracted for over 60% of participants, with remaining enrollment expected in Q2 2026. Real-time and accelerated stability studies of the CBD QuickStrip investigational product are ongoing.
Rapid Dose Therapeutics (OTCQB: RDTCF; CSE: DOSE) announced that its common shares began trading in the United States on the OTCQB Venture Market under ticker RDTCF on February 11, 2026. The move aims to increase U.S. investor access, visibility, liquidity, and engagement with North American life sciences investors.
The company will continue trading in Canada on the Canadian Securities Exchange under DOSE. The announcement highlights the QuickStrip™ oral thin film portfolio and frames the OTCQB listing as aligning with the company’s growth, partnership, and commercialization strategy.
Rapid Dose Therapeutics (OTCQB: RDTCF) launched its co-branded QuickStrip medical cannabis oral thin film in Brazil after ANVISA approved sublingual and buccal pharmaceutical routes on January 28, 2026. The product will be distributed via partners Nexxions and Entourage Phytolab.
Brazil reports 672,000 registered cannabis patients (up 56% YoY) and a 2025 market value of USD 856.53M, forecast to reach USD 1,546.74M by 2034 (CAGR 6.79%). ANVISA rules permit cultivation up to 0.3% THC and expand access for chronic disease treatment.
Rapid Dose Therapeutics (OTC:RDTCF) announced it will issue 362,708 common shares to satisfy $47,153.98 of accrued interest on amended secured convertible notes, at a deemed issue price of $0.13 per share based on the CSE closing price on December 31, 2025. The Common Shares are expected to be issued no later than January 15, 2026 and will be subject to a hold period expiring four months and one day after issuance.
The Notes were issued from a 2023 private placement totaling $3,134,445 principal and 15,672,225 warrants; holders of $3,084,445 in notes agreed to extend note and warrant maturities to November 30, 2026. The Notes carry 18% annual interest, compounded monthly, payable quarterly in shares.
Rapid Dose Therapeutics (OTC:RDTCF) extended the maturity of outstanding secured convertible notes issued in its 2023 private placement from Nov 30, 2025 to Nov 30, 2026. Noteholders representing $3,084,445 of principal agreed to the Extension; one holder with $50,000 was repaid in cash.
The Extension set interest at 18% per annum (up from 12%), compounded monthly and payable quarterly in common shares; conversion price remains $0.17. The company issued 1,356,758 common shares to satisfy $62,860.65 of accrued interest. Extension fees of 5% were payable in shares at $0.16, and certain insiders holding $1,696,371 of notes participated, receiving 530,115 extension-fee shares. All issued securities are held for four months and one day.
Rapid Dose Therapeutics (OTC:RDTCF) announced an agreement to extend the maturity dates of most secured convertible notes issued in its 2023 private placement from November 30, 2025 to November 30, 2026. Noteholders representing $3,084,445 of the aggregate $3,134,445 principal accepted the Extension; one $50,000 holder will be repaid in cash.
The Extension raises the notes' annual interest rate from 12% to 18%, compounded monthly, converts accrued interest of $62,860.65 into common shares (to be issued by Dec 15, 2025), and pays a 5% extension fee in shares at $0.16 per share. Related parties hold $1,696,371 of notes; the board approved the transaction and relied on MI 61-101 exemptions.
Rapid Dose Therapeutics (OTC:RDTCF) extended its exclusive pre-commercialization and development agreement with an international nicotine partner retroactive to June 19, 2025, for seven months, representing up to approximately $1.8 million CAD. The extension supports further evaluation of NicStrip™ oral thin films while the partner remains anonymous until a commercial deal is signed.
Key milestones: Health Canada submission filed Aug 4, 2025 for 1–4 mg formats; a GCP pharmacokinetic study launched June 2025; two PCT patent applications filed May 2025. NicStrip™ offers customizable strengths (1–12 mg) and multiple packaging options.
Rapid Dose (OTC:RDTCF) announced it will satisfy accrued interest on its secured convertible notes by issuing common shares. The Company expects to issue 592,533 Common Shares no later than October 15, 2025 at a deemed issue price of $0.16 per share, covering $94,806.23 of accrued interest payable as of September 30, 2025.
The Notes were issued across four tranches in 2023 as part of a private unit financing totaling $3,134,445 principal and 15,672,225 warrants. The Notes mature on November 30, 2025 and bear interest at 12.0% per annum, with interest payable quarterly in Common Shares based on the CSE closing price on the last trading day of each quarter. All issued shares will be subject to a four‑month plus one day hold period.